The treatment of behavioral and psychological symptoms of dementia: Weighing benefits and risks

Current Alzheimer Research

Volumn 13, Issue 10, 2016, Pages 1124-1133

  Zdanys, Kristina F ^a   Carvalho, André F ^b   Tampi, Rajesh R ^c   Steffens, David C ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agitation; Alzheimer s disease; Behavioral and psychological symptoms of dementia; Dementia; Depression; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; MELATONIN; MEMANTINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OXCARBAZEPINE; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AROMATHERAPY; BEHAVIOR DISORDER; CLINICAL ASSESSMENT; COGNITIVE BEHAVIORAL THERAPY; DEMENTIA; DEPRESSION; EMOTIONAL DISORDER; HUMAN; MENTAL DISEASE; NEUROIMAGING; PHOTOTHERAPY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK; CAREGIVER; COMPLICATION; MENTAL DISORDERS; MOOD DISORDERS; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; CAREGIVERS; DEMENTIA; HUMANS; MENTAL DISORDERS; MOOD DISORDERS;

EID: 84986879621     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160510121633     Document Type: Review

References (112)

1. Finkel SI, Burns A. BPSD Consensus Statement, International Psychogeriatric Association (1999).
2. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157(5): 708-14 (2000).
3. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23(2): 170-7 (2008).
4. Steffens DC. Separating mood disturbance from mild cognitive impairment in geriatric depression. Int Rev Psychiatry 20(4): 374-81 (2008).
5. Ford AH. Neuropsychiatric aspects of dementia. Maturitas 79(2): 209-15 (2014).
6. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16(11): 1043-53 (2001).
7. Tampi R, Williamson D, Muralee S, Mittal V, McEnerney N, Thomas J, et al. Behavioral and psychological symptoms of dementia: Part 1--Epidemiology, Neurobiology, Heritability, and Evaluation. Clin Geriatr 19(5): 41-46 (2011).
8. Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA. Psychosis in Alzheimer's disease. Biol Psychiatry 75(7): 542-52 (2014).
9. Cipriani G, Lucetti C, Nuti A, Danti S. Wandering and dementia. Psychogeriatrics 14(2): 135-42 (2014).
10. Allan CE, Valkanova V, Ebmeier KP. Depression in older people is underdiagnosed. Practitioner 258(1771): 2-3 (2014).
11. Low LF, Chilko N, Gresham M, Barter S, Brodaty H. An update on the pilot trial of consumer-directed care for older persons in Australia. Australas J Ageing 31(1): 47-51 (2012).
12. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31(12): 721-7 (1983).
13. Graf C. The Lawton Instrumental Activities of Daily Living (IADL) Scale. Medsurg Nurs 18(5): 315-6 (2009).
14. Sutor B, Rummans TA, Smith GE. Assessment and management of behavioral disturbances in nursing home patients with dementia. Mayo Clin Proc 76(5): 540-50 (2001).
15. Omelan C. Approach to managing behavioural disturbances in dementia. Can Fam Physician 52: 191-9 (2006).
16. Sattar SP, Padala PR, McArthur-Miller D, Roccaforte WH, Wengel SP, Burke WJ. Impact of problem alcohol use on patient behavior and caregiver burden in a geriatric assessment clinic. J Geriatr Psychiatry Neurol 20(2): 120-7 (2007).
17. Zucker DK, Livingston RL, Nakra R, Clayton PJ. B12 deficiency and psychiatric disorders: case report and literature review. Biol Psychiatry 16(2): 197-205 (1981).
18. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB. Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med 72(9): 862-73 (2010).
19. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 48: 9-15 (1987).
20. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(5 Suppl 6): S10-6 (1997).
21. Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr 8(3): 309-15; discussion 51-4 (1996).
22. Heyman A, Fillenbaum GG, Mirra SS. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): clinical, neuropsychological, and neuropathological components. Aging (Milano) 2(4): 415-24 (1990).
23. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 63(11): 2227-46 (2015).
24. Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother 44(10): 1624-32 (2010).
25. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy 24(9): 1177-85(2004).
26. Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging 2(4): 611-21 (2007).
27. Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc 62(4): 762-9.(2014).
28. Black W, Almeida OP. A systematic review of the association between the Behavioral and Psychological Symptoms of Dementia and burden of care. Int Psychogeriatr 16(3): 295-315 (2004).
29. Orgeta V, Qazi A, Spector AE, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev 1: CD009125 (2014).
30. Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry 20(7): 549-64 (2012).
31. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG, Old Age Task Force of the World Federation of Biological P. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 162(11): 1996-2021 (2005).
32. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A systematic review of the clinical effectiveness and costeffectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess 18(39): 1-226, v-vi (2014).
33. Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc 13(6): 503-06 e2 (2012).
34. Tampi R, Williamson D, Muralee S, Mittal V, McEnerney N, Thomas J, et al. Behavioral and psychological symptoms of dementia: Part 2--Treatment. Clin Geriatr 19(6): 31-40 (2011).
35. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev(2): CD008191 (2011).
36. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Dement 26(3): 169-83 (2011).
37. Sepehry AA, Lee PE, Hsiung GY, Beattie BL, Jacova C. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 29(10): 793-806 (2012).
38. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and costeffectiveness of sertraline and mirtazapine. Health Technol Assess 17(7): 1-166 (2013).
39. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry 202: 121-8 (2013).
40. Olafsson K, Jorgensen S, Jensen HV, Bille A, Arup P, Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 85(6): 453-6 (1992).
41. Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci 24: 168-78 (2009).
42. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 49(1): 13-9 (2003).
43. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 172(4): 400-8 (2004).
44. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 157: 894-901 (1990).
45. Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord 24(4): 360-4 (2010).
46. Mizukami K, Tanaka Y, Asada T. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 30(7): 1342-6 (2006).
47. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60(4): 616-31 (2012).
48. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev(4): CD004990 (2004).
49. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5(1): 60-9 (1997).
50. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev(3): CD003945 (2009).
51. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr 20(2): 293-308 (2008).
52. Yeh YC, Ouyang WC. Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. Kaohsiung J Med Sci 28(4): 185-93 (2012).
53. Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. Drugs Aging 25(3): 187-96 (2008).
54. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21(5): 813-24 (2009).
55. Lockhart IA, Orme ME, Mitchell SA. The efficacy of licensedindication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and metaanalysis. Dement Geriatr Cogn Dis Extra 1(1): 212-27 (2011).
56. Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. J Alzheimers Dis 39(3): 477-85 (2014).
57. Matsunaga S, Kishi T, Yasue I, Iwata N. Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. Neuropsychopharmacology. 19(2): pii pyv086.
58. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 42(1): 32-8 (2008).
59. Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci 33(1): 23-31 (2012).
60. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepine. South Med J 68(6): 719-24 (1975).
61. Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM, 3rd, Giordani B, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 147(12): 1640-5 (1990).
62. Ancill RJ, Carlyle WW, Liang RA, Holliday SG. Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 6(3): 141-6 (1991).
63. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, Jr., et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26(4): 494-504 (2002).
64. Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen 29(7): 565-74 (2014).
65. Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev(1): CD003802 (2006).
66. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4(4): 281-4 (2003).
67. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 28(3): 296-301 (2008).
68. Lanctot KL, Chau SA, Herrmann N, Drye LT, Rosenberg PB, Scherer RW, et al. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr 26(2): 239-46 (2014).
69. Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease. J Clin Psychiatry 73(6): 796-801 (2012).
70. Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 41(2): 346-9 (2007).
71. Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 74(8): 810-6 (2013).
72. Meeks TW, Jeste DV. Beyond the Black Box: What is The Role for Antipsychotics in Dementia? Curr Psychiatr 7(6): 50-65 (2008).
73. US Food and Drug Administration, FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Centre for Drug Evaluation and Research (2005).
74. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 170(1): 96-103 (2010).
75. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22): 2335-41 (2005).
76. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 59(1): 1-12 (2009).
77. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 26(1): 10-28 (2011).
78. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7(6): 492-500 (2006).
79. van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Olde Rikkert MG. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 22(10): 845-58 (2005).
80. Gareri P, Segura-Garcia C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging 9: 1363-73 (2014).
81. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165(7): 844-54 (2008).
82. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 3: Cd007726 (2013).
83. Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis 42(3): 915-37 (2014).
84. Tan L, Tan L, Wang HF, Wang J, Tan CC, Tan MS, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer's Res Ther 7(1): 20 (2015).
85. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12): 1359-69 (2011).
86. Cheung G, Stapelberg J. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a metaanalysis of randomised placebo-controlled trials. N Zealand Med J 124(1336): 39-50 (2011).
87. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 66(5): 633-7 (2005).
88. Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther 7(1): 45 (2015).
89. Pan YJ, Wu CS, Gau SS, Chan HY, Banerjee S. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled studies. Dement Geriat Cogn Disord 37(3-4): 125-40 (2014).
90. Zuidema SU, Johansson A, Selbaek G, Murray M, Burns A, Ballard C, et al. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr 27(11): 1849-59 (2015).
91. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging 25(6): 501-19 (2008).
92. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19(12): 1123-30 (2004).
93. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14(4): 361-70 (2006).
94. Gasto C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 23(1): 21-6 (2003).
95. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10(9): 732-47 (2005).
96. Rosenberg C, Lauritzen L, Brix J, Jorgensen JB, Kofod P, Bayer LB. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice. Psychopharmacol Bull 40(1): 63-73 (2007).
97. Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, et al. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry 38(1): 13-6 (2005).
98. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 26(5): 381-94 (2009).
99. Blackwell B. Hypertensive Crisis Due to Monoamine-Oxid Inhibitors. Lancet 2(7313): 849-50 (1963).
100. Volz H, Gleiter C. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 13(5): 341-55 (1998).
101. Iqbal MM, Basil MJ, Kaplan J, Iqbal MT. Overview of serotonin syndrome. Ann Clin Psychiatry 24(4): 310-8 (2012).
102. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 21(3): 454-63 (1999).
103. Anttila AK, Rasanen L, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three-to fourfold. Ann Pharmacother 35(10): 1221-3 (2001).
104. Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? J Affect Disord 146(2): 151-7 (2013).
105. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults--a systematic review. J Geriatr Psychiatry Neurol 25(1): 51-61 (2012).
106. Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 119(6): 478-81 (2006).
107. Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol 8(1): 81-91 (2012).
108. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry 59(12): 618-23 (2014).
109. Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 344: e2986 (2012).
110. Lechin F, van der Dijs B, Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom 65(4): 171-82 (1996).
111. Ungar A, Rafanelli M, Iacomelli I, Brunetti MA, Ceccofiglio A, Tesi F, et al. Fall prevention in the elderly. Clin Cases Miner Bone Metab 10(2): 91-5 (2013).
112. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother 13(6): 895-905 (2012).